Solutions

Accelerate adoption of new therapies and advance patient care

Leverage real-world data, powerful analytics, and the Truveta Language Model to support therapy development and access, care quality improvement, and public health.

How we can help

Safety

Fulfill post-market regulartory requirements and assess long-term product safety more efficiently with real-time data.

Truveta enables life sciences companies to:

  • Meet regulatory evidence standards faster and at lower cost by eliminating the need for expensive and long-running registries
  • Quickly assess the validity of potential safety signals with real-time data
  • Conduct studies assessing the long-term, real-world safety of different treatments with access to complete medical records, including notes and images

Assessing the safety of novel interventions

Comparative bleeding incidence 7 days post-procedure for pulmonary embolism interventions

 Read the research

HEOR

Evaluate clinical- and cost-effectiveness to differentiate products using real-world data from 30 health systems.

Truveta enables life sciences companies to:

  • Assess the clinical- and cost-effectiveness of therapies to inform access and reimbursement decisions
  • Generate scientific evidence on comparative effectiveness and long-term outcomes to connect the right patients to the right therapies
  • Analyze real-world treatment pathways and healthcare resource utilization patterns to inform access and engagement programs

Comparing real-world treatment outcomes

Hazard of cardiovascular events associated with SGLT2i vs metformin

 

Public health

Monitor disease trends and identify disparities in healthcare access and outcomes with EHR data from 100M+ patients across the US

Truveta enables government and academic research organizations to:

  • Monitor disease trends and vaccine safety with daily-updated data
  • Study maternal and child health with access to more than 1 million mother-child pairs
  • Analyze the impact of more than 45 SDOH variables on healthcare access and outcomes
  • Gauge the impact of policies on health outcomes, healthcare utilization, costs, and population health with complete EHR data linked to SDOH, mortality, and claims data

Respiratory virus-associated hospitalizations (from monitoring report)

Rate of weekly respiratory virus-associated hospitalizations compared to all hospitalizations since October 2019

 Read the report

Clinical trials

Validate trial design and supplement trial data with real-world arms.

Truveta enables life sciences companies to:

  • Build and analyze precise populations with complete data for 100M+ patients
  • De-risk clinical programs with dynamic, real-time analytics 
  • Generate evidence for real-world control arms using regulatory-grade data

Testing I/E criteria to de-risk clinical programs

Diagram detailing inclusion and exclusion criteria applied to a heart failure population in Truveta Data. The criteria encompass medication use, length of stay, outpatient encounters, laboratory results, comorbidities, and device use. The visual representation offers a comprehensive overview of the selection criteria, aiding in understanding the parameters used to define the study population.

Sample heart failure population with inclusion/exclusion criteria applied

 Read the webinar recap

Care quality

Real-time dashboard showing TAVR volumes, access by cohort, and adverse events  Monitor patient outcomes and benchmark to real-time, nationally representative EHR data.

Truveta enables healthcare organizations to:

  • Deliver more equitable, high-quality care by identifying disparities and gaps in care
  • Guide evidence-based decisions by linking treatment patterns to outcomes
  • Assess variations in care quality to support value-based care programs

Tracking procedure utilization and outcomes over time

Real-time dashboard showing TAVR volumes, access by cohort, and adverse events

Market access

Monitor and ensure patient access to therapies using real-time EHR data. 

Truveta enables life sciences companies to:

  • Assess product utilization and market share trends
  • Generate compelling evidence of real-world effectiveness and economic value to inform coverage and reimbursement decisions
  • Monitor and remediate the impact of potential supply chain shortages 

Assessing the impact of drug shortages

Rate of amphetamine/dextroamphetamine prescription fills per eligible population, stratified by age

Read the research

Research and development

Train AI models for discovery and product enhancement with complete and representative EHR data. 

Truveta enables life sciences companies to:

  • Identify patient subgroups most likely to respond to a therapy or experience specific medical events
  • Discover product enhancement or innovation opportunities using AI trained on medical records

Exploring the association between heart failure and medication use

Population clustering to facilitate drug discovery

How we can help

Safety

HEOR

Public health

Clinical trials

Care quality

Market access

Research & development

Safety

Fulfill post-market regulatory requirements and assess long-term product safety more efficiently with real-time data.

Truveta enables life sciences companies to:

^
Meet regulatory evidence standards faster and at lower cost by eliminating the need for expensive and long-running registries
^

Quickly assess the validity of potential safety signals with real-time data

^

Conduct studies assessing the long-term, real-world safety of different treatments with access to complete medical records data, including notes and images

Assessing the safety of novel interventions

Comparison table from a scientific publication using Truveta Data to illustrate bleeding events associated with two medical devices for treating pulmonary embolism: the USCDT (Unspecified Superiority Clot Dissolver) and MT (Standard Mechanical Thrombectomy). The data is presented for two distinct time periods—2009 to 2023 (primary analysis) and 2018 to 2023 (contemporary analysis). Bleeding events are categorized into six types, with results presented as counts and percentages. Statistical significance is indicated by p-values, providing insights into the safety profiles of the two devices over time.

Comparative bleeding incidence 7 days post-procedure for pulmonary embolism interventions

HEOR

Evaluate clinical- and cost-effectiveness to differentiate products using real-world data from 30 health systems.

Truveta enables life sciences companies to:

^

Assess the clinical- and cost-effectiveness of therapies to inform access and reimbursement decisions

^

Generate scientific evidence on comparative effectiveness and long-term outcomes to connect the right patients to the right therapies

^

Analyze real-world treatment pathways and healthcare resource utilization patterns to inform access and engagement programs

Comparing real-world treatment outcomes
October 2023 Respiratory Viruses hospitalizations trend report

Hazard of cardiovascular events associated with SGLT2i vs metformin

Public health

Monitor disease trends and identify disparities in healthcare access and outcomes with EHR data lfrom 100M patients across the US.

Truveta enables government and academic research organizations to:

^

Monitor disease trends and vaccine safety with daily-updated data

^

Study maternal and child health with access to more than 1 million mother-child pairs

^
Analyze the impact of more than 45 SDOH variables on healthcare access and outcomes
^

Gauge the impact of policies on health outcomes, healthcare utilization, costs, and population health with complete EHR data linked to SDOH, mortality, and claims data

Respiratory virus-associated hospitalizations
Truveta Research uses EHR data to explore trends in monthly respiratory virus-associated hospitalizations for RSV, COVID, influenza, parainfluenza, HMPV, and rhinovirus.

Rate of weekly respiratory virus-associated hospitalizations compared to all hospitalizations since October 2019

Clinical trials

Validate trial design and supplement trial data with real-world arms.

Truveta enables life sciences companies to:

^

Build and analyze precise populations with complete data for 100M+ patients

^
De-risk clinical programs by optimizing trial design with dynamic, real-time analytics
^

Generate evidence for real-world control arms using regulatory-grade data

Testing I/E criteria to de-risk clinical programs

Diagram detailing inclusion and exclusion criteria applied to a heart failure population in Truveta Data. The criteria encompass medication use, length of stay, outpatient encounters, laboratory results, comorbidities, and device use. The visual representation offers a comprehensive overview of the selection criteria, aiding in understanding the parameters used to define the study population.

Sample heart failure population with inclusion/exclusion criteria applied

Care quality

Monitor patient outcomes and benchmark to real-time, nationally representative EHR data.

Truveta enables healthcare organizations to:

^

Deliver more equitable, high-quality care by identifying disparities and gaps in care

^

Guide evidence-based decisions by linking treatment patterns to outcomes

^

Assess variations in care quality to support value-based care programs

Tracking procedure utilization and outcomes over time
October 2023 Respiratory Viruses hospitalizations trend report

Real-time dashboard showing TAVR volumes, access by cohort, and adverse events

Market access

Monitor and ensure patient access to therapies using real-time EHR data.

Truveta enables life sciences companies to:

^

Assess product utilization and market share trends

^

Generate compelling evidence of real-world effectiveness and economic value to inform coverage and reimbursement decisions

^

Monitor and remediate the impact of potential supply chain shortages

Assessing the impact of drug shortages

Truveta Research explores the potential impact of Adderall shortage using EHR data to explore trends in prescription fills for patients with ADHD

Rate of amphetamine/dextroamphetamine prescription fills per eligible population, stratified by age

Research and development

Train AI models for discovery and product enhancement with complete and representative EHR data.

Truveta enables life sciences companies to:

^

Identify patient subgroups most likely to respond to a therapy or experience specific medical events

^
Discover product enhancement or innovation opportunities using AI trained on medical records
Exploring the association between heart failure and medication use
Population clustering visualization featuring two panes in Truveta Studio. The first pane explores the absence or presence of Type 2 diabetes, with distinct clusters or patterns representing different groups within the population. The second pane depicts heart failure rates, offering insights into how these rates vary or cluster within the analyzed population. The visualization provides a comprehensive overview of the relationships between Type 2 diabetes and heart failure prevalence.

Population clustering to facilitate drug discovery

Why Truveta

Regulatory-grade EHR data

Truveta offers complete, timely, and clean EHR data linked with SDOH, mortality, and claims data for more than 100 million patients representing the full diversity of the US.

Powerful analytics

Truveta Studio provides immediate access to Truveta Data, powerful analytics and AI, and evidence fit for regulatory submission.

Trusted health system relationships

Truveta members share in our commitment to data quality, adhering to rigorous standards for representativeness, completeness, timeliness, and cleanliness from the point of ingestion.

Trusted by leading life science, government, academic, health system, and research organizations.